SCIENCE@home

Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib

S. Karovic,EF Shiuan,S.-Q. Zhang,H. Cao,ML Maitland

Published 2016 in Clinical and Translational Science

ABSTRACT

Novel characterization of patterns of adverse events (AEs) of kinase inhibitors (KIs) could reveal new insights on human molecular physiology and methods to improve the therapeutic index of KIs. Incidence and severity of AEs for each of 157 patients enrolled in sorafenib clinical trials were determined for three clinically relevant treatment intervals: weeks 0–3, weeks 3–7, and after 7 weeks. The most common within patient co‐occurrences were mucositis with dermatologic events: hand‐foot syndrome (HFS; odds ratio [OR] = 4.36; p = 0.0017) and rash (OR = 5.32; p < 0.001). Prevalence of severe: alopecia (p = 0.02), diarrhea (p < 0.001), and fatigue (p = 0.005) increased over the course of therapy. Incidence of HFS (60%) and diarrhea (25%) increased up to a minimum steady‐state concentration (approximately 5 mcg mL‐1) and plateaued thereafter. Common AEs of sorafenib occur in distinct temporal and tissue distribution patterns and this analysis identified unrecognized relationships among mechanism‐dependent and independent effects of a KI.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-31 of 31 references · Page 1 of 1

CITED BY

Showing 1-10 of 10 citing papers · Page 1 of 1